NewsRamp is a PR & Newswire Technology platform that enhances press release distribution by adapting content to align with how and where audiences consume information. Recognizing that most internet activity occurs outside of search, NewsRamp improves content discovery by programmatically curating press releases into multiple unique formats—news articles, blog posts, persona-based TLDRs, videos, audio, and Zero-Click content—and distributing this content through a network of news sites, blogs, forums, podcasts, video platforms, newsletters, and social media.
FAQ: Soligenix Inc. and the Urgent Need for Rare Disease Therapies
TL;DR
Soligenix's HyBryte nearing final trial completion offers investors potential advantage in rare disease market with over 30 million affected Americans lacking FDA-approved therapies.
Soligenix's HyBryte uses synthetic hypericin sodium in photodynamic therapy with visible light, now in final confirmatory Phase 3 trial before global regulatory submissions.
Soligenix's treatments for rare diseases like cutaneous T-cell lymphoma address unmet medical needs for millions, making tomorrow better through accessible therapies for chronic conditions.
Soligenix develops HyBryte for cutaneous T-cell lymphoma using visible light therapy and also works on ricin and COVID-19 vaccines with heat stabilization technology.
Found this article helpful?
Share it with your network and spread the knowledge!
The APR is titled 'Chronic Rare Diseases in an Aging America: Why HyBryte and Federal Policy Matter Now' and focuses on the growing impact of chronic and rare conditions on older adults in the U.S., highlighting the urgent need for FDA-approved therapies.
Soligenix Inc. (NASDAQ: SNGX) is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need.
HyBryte™ (also known as SGX301 or synthetic hypericin sodium) is Soligenix's lead candidate. It is a novel photodynamic therapy that utilizes safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL).
HyBryte™ is now in the final confirmatory trial needed before the company can make global marketing submissions to regulatory authorities for approval.
The timing is significant because Soligenix's progress with HyBryte™ coincides with the current administration advancing new health policy initiatives specifically related to chronic and rare diseases.
Other programs include expanding synthetic hypericin (SGX302) into psoriasis, developing dusquetide (SGX942) for inflammatory diseases like oral mucositis, developing SGX945 for Behçet’s Disease, and a first-in-class innate defense regulator (IDR) technology.
This segment develops vaccine candidates, including RiVax® for ricin toxin, vaccines for filoviruses like Marburg and Ebola, and CiVax™ for the prevention of COVID-19. These programs use the company's proprietary ThermoVax® heat stabilization platform.
This business segment has been supported with government grant and contract funding from agencies including the National Institute of Allergy and Infectious Diseases (NIAID), the Defense Threat Reduction Agency (DTRA), and the Biomedical Advanced Research and Development Authority (BARDA).
The latest news and updates are available in the company’s newsroom at https://ibn.fm/SNGX.
More than 30 million Americans are affected by chronic and rare conditions, and most of these conditions lack FDA-approved therapies, creating a significant unmet medical need.
Curated from InvestorBrandNetwork (IBN)
